Jury Verdicts & Settlements

Latest jury verdicts, settlements, and legal outcome analysis

Jury Awards $12.5M in Samsung Smartphone Patent Verdict

A federal jury in the Eastern District of Texas found that Samsung's Galaxy S20 through S23 smartphones infringed a patent covering adaptive MIMO/SIMO mode selection technology licensed exclusively to Empire Technology Development LLC. The jury rejected claims that Samsung infringed a second patent related to channel estimation and found the infringement was not willful, awarding Empire a lump sum royalty of $12,500,000.

Patent Infringement

Jury Clears AT&T in Patent Fight Over 5G Network Tech

A jury in the Eastern District of Texas ruled that AT&T Corp., AT&T Mobility LLC, AT&T Mobility II LLC and AT&T Services Inc. did not infringe a patent held by Daingean Technologies Ltd. covering wireless communication technology tied to 4G and 5G network standards. The verdict, delivered after a trial before Judge Rodney Gilstrap, cleared AT&T of liability on the sole claim submitted to the jury, and the Court later entered judgment naming AT&T the prevailing party and directing it to recover its costs from Daingean.

Patent Infringement

Samsung Ordered to Pay $3M in WiFi Patent Infringement Case

A federal jury in the Eastern District of Texas ordered Samsung Electronics to pay $3 million to Vasu Holdings, LLC after finding that Samsung's products infringed a patent covering technology that allows mobile devices to switch seamlessly between cellular and WiFi networks without dropping an active call or data session. The jury sided with Vasu on one of three patents that went to trial, finding Claim 1 of U.S. Patent No. 8,886,181 both infringed and valid. It returned no-infringement verdicts on the remaining two patents.

Patent Infringement

Samsung Loses $78.5M Patent Verdict Over Smart TV Ad Tech

A federal jury in the Eastern District of Texas awarded Anonymous Media Research Holdings $78.5 million after finding that Samsung Electronics infringed patents covering automatic content recognition technology embedded in its Smart TV advertising platform, Samsung Ads. The jury found Samsung infringed all five claims put before it — across two patents covering ACR data scrubbing and media measurement methods — and rejected Samsung's argument that the patents were invalid. The award was split 52% to the '848 Patent and 48% to the '911 Patent.

Patent Infringement

Jury Awards $190M in Wi-Fi Calling Patent Infringement Case

A federal jury in the Eastern District of Texas found Verizon Wireless liable for infringing a patent covering technology that allows phone calls to switch between Wi-Fi and cellular networks without dropping. The jury awarded $190 million in damages to Aspen Networks, Inc., rejecting Verizon's arguments that the patent was invalid.

Patent Infringement

Jury Awards Running Royalty in Wireless Patent Infringement

A jury in the Eastern District of Texas found Samsung Electronics willfully infringed four patents owned by Collision Communications covering wireless signal processing and multi-user detection technology. The jury awarded $445,494,160.00 as a running royalty. The Court entered judgment affirming the verdict but declined to enhance damages despite the willfulness finding.

Patent Infringement

Jury Awards $278M in Wireless Patent Infringement Verdict

A jury in the Eastern District of Texas returned a unanimous verdict finding that Samsung Electronics infringed two wireless communications patents owned by Headwater Research LLC. The jury awarded $278,791,460 as a lump sum reasonable royalty for infringement of U.S. Patent Nos. 8,406,733 and 9,198,117, which covered automated device provisioning and secure wireless messaging technology used in Samsung's Galaxy phones, tablets, Knox-enabled devices, and Tizen-based products.

Patent Infringement

Patent Infringement Verdict: Fully Human Antibody Platform

A federal jury in Delaware ordered Teneobio Inc. and Amgen Inc. to pay $20,203,704 in damages to Harbour Antibodies after determining that the Defendants' antibody discovery platform literally infringed claim 2 of U.S. Patent Number 10,906,970. While the jury unanimously found that Teneobio's UniRat platform met the "cloning said recombined heavy chain locus" element, it rejected the Plaintiffs' claim that the infringement was willful. The jury also systematically rejected all of Teneobio's invalidity defenses, including allegations of obviousness, lack of enablement, and inadequate written description, validating the structural integrity of Harbour's transgenic rodent technology.

Patent Infringement

$41M Cancer Drug Patent Verdict Overturned on Appeal

A Texas jury found that Daiichi Sankyo's cancer drug Enhertu infringed Seagen's antibody-drug conjugate patent, awarding $41.8 million in damages and finding the infringement willful. However, the Federal Circuit later reversed, ruling that Seagen's patent could not claim priority to its 2004 application since it failed to specifically describe the narrow group of amino acid combinations later claimed, and that the patent failed to enable the full scope of its claims without undue experimentation, rendering it invalid.